Review of #ASCO26 - Gyn Cancer Oral Abstract Sessions, May 29th sessions

I did not attend ASCO in person this year but rather I watched sessions live.  When not available live I watched session On Demand the next day.  I continued the tradition I started when I attended meetings in person.  I posted on X (Twitter) summarizing and sharing slides from the presentations. 

The Oral Abstract Session for Gynecologic Cancers was held on Friday, May 29th. My focus what on ovarian cancer treatment research. ( Although there is one endometrial trial in this post) 

 Endometrial Cancer: Ruby Trial Dostarlimab + Chemo Abs 5501

Virtual #ASCO26 Day 1 GYN Oral abstracts long-term survival rates dostarlimab + chemotherapy (dMMR/MSI-H) endometrial cancer in RUBY trial. Matthew A. Powell, MD #gyncsm
OS benefit 16 months | Mixed cure model estimate used in study pic.twitter.com/ofZVX3nMti

— Dee Sparacio (@womenofteal) May 29, 2026

 Ovarian Cancer  NRG GY018  Abs 5502

Virtual Day 1 #ASCO26 Gyn Oral abstracts #gyncsm 5502 OS analysis pembrolizumab plus carboplatin/paclitaxel (CP) as compared to CP plus placebo (PBO) in the NRG-GY018 trial , FDA approval received for EC pic.twitter.com/aYWN5H6KlG

— Dee Sparacio (@womenofteal) May 29, 2026

Ovarian Cancer ROSELLA trial  Abs 5503

Gyn oral abstracts #ASCO26 #gyncsm
OS analyses for prior taxane use in the phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel versus nab-paclitaxel monotherapy in patients OC (GOG-3073)
*Prior taxane use did not reduce effect of relacorilant, No relacorilant fatal AE's. pic.twitter.com/NxvrTN1WfQ

— Dee Sparacio (@womenofteal) May 29, 2026

 Late Breaking Abstract CHIPRO  LBA 5504

Gyn oral ab #ASCO26 #gyncsm A phase III CHIPRO study of chiauranib ( Aurora B Kinase inhibitor) plus weekly paclitaxel for platinum-resistant / refractory ovarian cancer. LBA5504
PFS 4.57 mo , OS no significant difference between arms, most AE's hematological pic.twitter.com/c3UHujM7Ae

— Dee Sparacio (@womenofteal) May 29, 2026

 Ovarian Cancer CHRONO Abs 5505

#ASCO26 Gyn Oral Abstracts #gyncsm CHRONO: A randomized ph II trial of the chronology of surgery after neoadjuvant chemotherapy for ovarian cancer. ( 3 cycles of chemo then surgery vs 6 cycles chemo then surgery.) 10% each arm HIPEC. QOL no significant difference pic.twitter.com/LG7TvyQOS7

— Dee Sparacio (@womenofteal) May 29, 2026

 

Distillation of these studies : 

#ASCO26 #gyncsm Distillation Rosella / Chipro and Chrono Dr Fuh pic.twitter.com/iDr5CQbmRR

— Dee Sparacio (@womenofteal) May 29, 2026

Ovarian Cancer Phase 2 MIRV trial Abs 5506

#ASCO26 #gyncsm Gyn Onc Oral Abstracts
5506 A randomized phase II trial of mirvetuximab soravtansine in folate receptor alpha (FRα)–high recurrent OC eligible for platinum-based chemotherapy (MIROVA/AGO-OVAR 2.34). Higher response rate did not translate to prolonged PFS pic.twitter.com/nB1tXrCzmc

— Dee Sparacio (@womenofteal) May 29, 2026

 

I'll post over the next few days other ASCO sessions including - Rapid Oral Abstracts, Surgery vs NACT, and the Poster Session. 

Dee

Every Day is a Blessing!